SLIDE 1
Appendix
Potential target patient populations 2018
2
Oncology Hemophilia A Ophthalmology Infectious diseasese Neuroscience Immunology
Appendix Potential target patient populations 2018 Oncology - - PowerPoint PPT Presentation
Appendix Potential target patient populations 2018 Oncology - - PowerPoint PPT Presentation
Appendix Potential target patient populations 2018 Oncology Hemophilia A Ophthalmology Infectious diseasese Neuroscience Immunology 2 Herceptin + Perjeta, Tecentriq: HER2+ early Breast Cancer (eBC) 2018 estimates for number of patients 3
SLIDE 2
SLIDE 3
Herceptin + Perjeta, Tecentriq: HER2+ early Breast Cancer (eBC)
3
Source: Roche/Genentech
2018 estimates for number of patients
SLIDE 4
Perjeta, Herceptin, Kadcyla, Tecentriq: HER2+ metastatic Breast Cancer (mBC)
4
2018 estimates for number of patients
Source: Roche/Genentech; Kadcyla in collaboration with ImmunoGen
- The target US and EU 5 population for 1L HER2+ mBC is ~19,300 patients (7,800 de novo and 11,400 adjuvant relapse)
- The target US and EU 5 population for 2L-4L HER2+ mBC is ~34,900 patients (~19,700 US/~15,200 Top 5 EU)
SLIDE 5
Ipatasertib: HER2-/HR+ 1L and recurrent mBC
5
2018 estimates for number of patients
Source: Roche/Genentech; *2/3L includes HR+ patients who received chemotherapy in 1L; Patients may receive up to 7 lines of treatment, but 4L+ patients are not included; Ipatasertib in collaboration with Array BioPharma
SLIDE 6
Tecentriq, ipatasertib: Triple Negative Breast Cancer (TNBC)
6
2018 estimates for number of patients
Source: Roche/Genentech; Ipatasertib in collaboration with Array BioPharma
SLIDE 7
Avastin: Ovarian Cancer (OC)
7
2018 estimates for number of patients
Source: Roche/Genentech
SLIDE 8
Tecentriq, Avastin: Non Squamous Non Small Cell Lung Cancer (NSq NSCLC)
8
2018 estimates for number of patients
Source: Roche/Genentech
SLIDE 9
Alecensa: ALK+ metastatic Non Small Cell Lung Cancer (mNSCLC)
9
2018 estimates for number of patients
Source: Roche/Genentech; Alecensa in collaboration with Chugai
SLIDE 10
Tecentriq: Small Cell Lung Cancer (SCLC)
10
2018 estimates for number of patients
Source: Roche/Genentech
SLIDE 11
Zelboraf: Adjuvant BRAF+ stage IIc and III Melanoma
11
2018 estimates for number of patients
Source: Roche/Genentech; Zelboraf in collaboration with Plexxikon, a member of Daiichi Sankyo Group
SLIDE 12
Zelboraf: 1L BRAF+ metastatic Melanoma (mM)
12
2018 estimates for number of patients
Source: Roche/Genentech; Zelboraf in collaboration with Plexxikon, a member of Daiichi Sankyo Group
SLIDE 13
Erivedge: Advanced Basal Cell Carcinoma (BCC)
13
2018 estimates for number of patients
Source: Roche/Genentech
SLIDE 14
Avastin: Colorectal Cancer (CRC)
14
- The target population for Avastin in 1L CRC is ~124,000 patients and in 2L CRC ~78,600 patients
2018 estimates for number of patients
Source: Roche/Genentech
SLIDE 15
Tecentriq: Adjuvant Muscle Invasive Bladder Cancer (MIBC)
15
2018 estimates for number of patients
Source: Roche/Genentech
SLIDE 16
Tecentriq: Metastatic Urothelial Bladder Cancer (mUBC)
16
2018 estimates for number of patients
Source: Roche/Genentech
SLIDE 17
Tecentriq: Renal Cell Carcinoma (RCC)
17
2018 estimates for number of patients
Source: Roche/Genentech
SLIDE 18
Gazyva, Rituxan: Indolent Non-Hodgkin`s Lymphoma (iNHL)
18
2018 estimates for number of patients
Source: Roche/Genentech; Gazyva in collaboration with Biogen
SLIDE 19
Polatuzumab vedotin, Rituxan: Aggressive Non-Hodgkin`s Lymphoma (aNHL/DLBCL)
19
2018 estimates for number of patients
Source: Roche/Genentech; Polatuzumab vedotin in collaboration with Seattle Genetics; DLBCL=diffuse large B-Cell Non-Hodgkin’s lymphoma;
SLIDE 20
Gazyva, Venclexta, Rituxan: Chronic Lymphocytic Leukemia (CLL)
20
2018 estimates for number of patients
Source: Roche/Genentech; Gazyva in collaboration with Biogen; Venclexta in collaboration with AbbVie
SLIDE 21
Venclexta, idasanutlin: Acute Myeloid Leukemia (AML)
21
2018 estimates for number of patients
Source: Roche/Genentech; Venclexta in collaboration with AbbVie
SLIDE 22
Venclexta: Multiple Myeloma (MM)
22
2018 estimates for number of patients
Source: Roche/Genentech; Venclexta in collaboration with AbbVie
SLIDE 23
23
Oncology Hemophilia A Ophthalmology Infectious diseasese Neuroscience Immunology
SLIDE 24
Hemlibra: Hemophilia A
24
2018 estimates for number of patients
Source: Roche/Genentech; Hemlibra in collaboration with Chugai
SLIDE 25
25
Oncology Hemophilia A Ophthalmology Infectious diseasese Neuroscience Immunology
SLIDE 26
Faricimab, Port Delivery System (PDS), Lucentis: Age-related Macular Degeneration (AMD)
26
2018 estimates for number of patients
Source: Roche/Genentech
2,0m 1,8m 1,7m 2,1m 1,8m 1,6m
SLIDE 27
Faricimab, Port Delivery System (PDS), Lucentis: Diabetic Macular Edema (DME)
27
2018 estimates for number of patients
Source: Roche/Genentech
2,4m 1,7m 1,2m 2,0m 1,3m 0,9m
SLIDE 28
Port Delivery System (PDS), Lucentis: Retinal Vein Occlusion (RVO)
28
2018 estimates for number of patients
Source: Roche/Genentech
SLIDE 29
29
Oncology Hemophilia A Ophthalmology Infectious diseasese Neuroscience Immunology
SLIDE 30
Baloxavir marboxil: Influenza A & B
30
2018 estimates for number of patients
Source: Roche/Genentech; Baloxavir marboxil co-developed with Shionogi with Roche holding worldwide license excluding Japan and Taiwan
SLIDE 31
31
Oncology Hemophilia A Ophthalmology Infectious diseasese Neuroscience Immunology
SLIDE 32
Ocrevus: Multiple Sclerosis (MS)
32
2018 estimates for number of patients 2018 estimates for number of patients
Source: Roche/Genentech
SLIDE 33
Risdiplam (RG7916): Spinal Muscular Atrophy (SMA)
33
2018 estimates for number of patients
Source: Roche/Genentech; Risdiplam in collaboration with PTC Therapeutics and SMA Foundation
SLIDE 34
Myostatin inhibiting adnectin fusion protein (RG6206): Duchenne Muscular Dystrophy (DMD)
34
2018 estimates for number of patients
Source: Roche/Genentech
SLIDE 35
HTT-ASO (RG6042): Huntington’s Disease (HD)
35
2018 estimates for number of patients
Source: Roche/Genentech; HTT-ASO licensed from IONIS Pharmaceuticals
SLIDE 36
Balovaptan (RG7314): Autism Spectrum Disorder (ASD)
36
There are no FDA approved pharmacologic treatments for the core symptoms of ASD so today no one is treated with a pharmacologic for the core symptoms of Autism Spectrum Disorder* 2018 estimates for number of patients
Source: Roche/Genentech; *Pharmacologics for associated symptoms of Autism are available
SLIDE 37
Crenezumab, gantenerumab: Alzheimer’s Disease (AD)
37
2018 estimates for number of patients
Source: Roche/Genentech; aMCI=amnestic mild cognitive impairment; Crenezumab in collaboration with AC Immune; Gantenerumab in collaboration with MorphoSys
SLIDE 38
Satralizumab (RG6168): Neuromyelitis Optica (NMO)
38
2018 estimates for number of patients
Source: Roche/Genentech; Clinical developpment by Chugai
SLIDE 39
Prasinezumab (RG7935): Parkinson’s Disease (PD)
39
2018 estimates for number of patients
Source: Roche/Genentech; H&Y: Hoehn & Yahr scale; Prasinezumab in collaboration with Prothena
SLIDE 40
40
Oncology Hemophilia A Ophthalmology Infectious diseasese Neuroscience Immunology
SLIDE 41
Esbriet: Idiopathic Pulmonary Fibrosis (IPF)
41
2018 estimates for number of patients
Source: Roche/Genentech
SLIDE 42
Xolair: Moderate to severe Asthma
42
2018 estimates for number of patients
Source: Roche/Genentech
SLIDE 43
Actemra , Rituxan: Rheumatoid Arthritis (RA)
43
Global target population for Actemra and Rituxan in rheumatoid arthritis is ~1.2M biologics eligible patients. US patients treated with biologics by line
- f therapy (thousands)
2018 estimates for number of patients
Source: Roche/Genentech; Actemra in collaboration with Chugai
SLIDE 44
Actemra: Systemic Juvenile Idiopathic Arthritis (sJIA)
44
2018 estimates for number of patients
Source: Roche/Genentech; Actemra in collaboration with Chugai
SLIDE 45
Actemra: Polyarticular Juvenile Idiopathic Arthritis (pJIA)
45
2018 estimates for number of patients
Source: Roche/Genentech; Actemra in collaboration with Chugai
SLIDE 46
Actemra: Giant Cell Arteritis (GCA)
46
2018 estimates for number of patients
Source: Roche/Genentech; Actemra in collaboration with Chugai
SLIDE 47
Etrolizumab: Ulcerative Colitis (UC)
47
2018 estimates for number of patients
Source: Roche/Genentech
SLIDE 48
Etrolizumab: Crohn’s Disease (CD)
48
2018 estimates for number of patients
Source: Roche/Genentech
SLIDE 49